Eli Lilly, Profluent Target Complex Genetic Diseases With AI-Driven Custom DNA Tools

Profluent and Eli Lilly partner to develop AI-designed DNA editing tools, with deal value reaching $2.25 billion in milestones and royalties.

Profluent Enters Strategic Partnership with Lilly to Develop AI-Designed Recombinases for Genetic Medicine, Will Be Eligible For Up To $2.25B In Development And Commercial Milestone Payments

Profluent, the frontier AI company pioneering large-scale foundation models for protein design, today announced a multi-program strategic research collaboration with Eli Lilly and Company ("Lilly") to develop and

Profluent Partners With Eli Lilly To Develop, Commercialize Custom Site-Specific Recombinases For Diseases With Unmet Needs

Profluent, the frontier AI company pioneering large-scale foundation models for protein design, today announced a multi-program strategic research collaboration with Eli Lilly and Company ("Lilly") to develop and

4 Health Care Stocks Whale Activity In Today's Session

Earnings Volatility Watch: What To Expect From Sandisk and 5 Mag Seven Stocks This Week

SanDisk faces a 16.57% implied move and 5 Magnificent Seven names report this week — $18.59 trillion in market cap walks into Q1 2026 earnings.

Lilly To Acquire Ajax Therapeutics For Up To $2.3 Billion In Cash, Inclusive Of An Upfront Payment And Subsequent Payments

Eli Lilly and Company (NYSE:LLY) and Ajax Therapeutics, Inc. ("Ajax"), a biopharmaceutical company developing next generation JAK inhibitors for patients with myeloproliferative neoplasms (MPNs), today announced a

Deal Dispatch: QXO Nabs TopBuild For $17 Million, Voya Financial Urged To Evaluate Strategic Options, Pat McGrath Exits Chapter 11

Major M&A deals this week include Eli Lilly buys Kelonia for $7 billion, Honeywell sells PSS to Brady Corp., KSL buys Invited Clubs.

Hims & Hers Positions Itself As Supply Anchor In Hormone Therapy Crunch

Hims & Hers expands GLP-1 access, partners with drugmakers, and addresses estrogen patch shortages amid rising menopause care demand.

Hims and Hers CEO In X Post, Said: As Of This Morning, Providers On Our Platform Can Now Send Prescriptions For Zepbound Vials And Kwikpen, As Well As Foundayo, To The Lillydirect Pharmacy An

https://x.com/AndrewDudum/status/2047292307217825796?s=20

Large Drugmakers Eye Inhibrx Cancer Drugs Valued Over $8 Billion, Stock Surges

Inhibrx explores spin-off of INBRX-106 amid Big Pharma interest, with potential valuation exceeding $9 billion pending trial outcomes.